Juvenescence has named Dr Richard Marshall CBE as its CEO, as of 16 January. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the board as Executive Chairman. Dr Marshall brings over twenty years of business leadership to the company, with fifteen years at GSK culminating in his position as Vice President, Head of the Fibrosis & Lung Injury Discovery Performance Unit (DPU). Recently, Dr Marshall was Senior Vice President, Global Development Head, Respiratory & Immunology of AstraZeneca. Dr Marshall was awarded a CBE in the 2021 Queen’s Honours List for his contribution to UK science and COVID-19.
The Swedish healthtech company Encare is expanding to Japan and Austria - Encare's solution is now implemented in more than 25 countries. Far-reaching discussions with potential customers in additional countries are ongoing. During the autumn, the Swedish HealthTech company Encare expanded into two more new markets, Japan and Austria.
The suicide rate amongst young tradesmen is more than double that of other men and it is getting worse. Daniel Allen and Edward Ross founded TradeMutt when Daniel lost a close friend to suicide in 2015. TradeMutt is an innovative social impact workwear brand designed to start conversations about mental health with eye-catching colourful shirt designs.
Skillsoft, a platform for transformative learning experiences, announced it has entered into a content partnership with GoodHabitz, a provider of online skills training and professional development based in the Netherlands. Skillsoft and GoodHabitz will offer clients and learners a more comprehensive content library to support well-being in the workplace, and a broad range of skills, including personal productivity, leadership development, and communication.
Dedicated to researching and developing high-quality and scientifically-proven products, Biogency is an Australian local biotechnology research, development and supply company made up of leading healthcare professionals, academic researchers and naturopaths with the vision of creating the most innovative and effective health and beauty products. The Founders are group of PhD graduates from the University of Sydney Faculty of Pharmacy specialising their studies in life science with R&D Director Guanchen Sun leading the team of experts. The development of Synext saw the creation of an Aussie first NAD+ compounding formula supplement with multiple key ingredients created by the Sydney-based team.
Boehringer Ingelheim announces that the Shareholders have appointed Paola Casarosa and Shashank Deshpande to the Board of Managing Directors. They will succeed Michel Pairet, responsible for the Innovation Unit, and Jean Scheftsik de Szolnok, responsible for the Animal Health Business Unit, who informed the firm of their wish to retire at the end of next year.
Two million women in Australia have recently gone through menopause, and 80,000 women move into the postmenopausal stage every year - according to research by Australasian Menopause Society (AMS) and AIA Australia. And research from the UK revealed this year that "women with at least one problematic menopausal symptom [are] 43% more likely to have left their jobs by the age of 55."
Z Capital Partners, L.L.C., the private equity fund management arm of Z Capital Group, L.L.C. (ZCG), a privately held merchant bank, announced that affiliates of ZCG have acquired Universal Marine Medical Supply International (Unimed), the provider of pharmaceutical and medical solutions to the maritime industry, serving both commercial and cruise end markets.
AGIC Capital (AGIC), a growth-oriented private equity firm with $2.2 billion of assets under management, announced that it had acquired a majority stake in ATEC Pharmatechnik GmbH. The sellers, ATEC’s founder and Chief Executive Officer, Hans-Werner Mumm, and family-backed Mittelstand investor HANNOVER Finanz Group, will remain invested in the Company, and Hans-Werner Mumm will continue to act as its Chief Executive Officer.
The fast-growing global health & wellness industry is now worth $1.5 trillion and is projected to grow at a rate of 5-10% per year according to Mckinsey & Company. While every company rushes to bring new products to market to take a slice of the revenue opportunity, consumers are faced with a different dilemma. What innovations or brands can they trust?